Weill Cornell Medicine has been awarded a five-year, $9 million Program Project Grant from NCI to better understand how and why patients with an aggressive and incurable form of lymphoma initially respond to treatment, only to relapse over time.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe